WO2008148492A8 - Neurofilamental proteins as biomarker for alzheimer's disease - Google Patents

Neurofilamental proteins as biomarker for alzheimer's disease Download PDF

Info

Publication number
WO2008148492A8
WO2008148492A8 PCT/EP2008/004237 EP2008004237W WO2008148492A8 WO 2008148492 A8 WO2008148492 A8 WO 2008148492A8 EP 2008004237 W EP2008004237 W EP 2008004237W WO 2008148492 A8 WO2008148492 A8 WO 2008148492A8
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
disease
alzheimer
variant
level
Prior art date
Application number
PCT/EP2008/004237
Other languages
French (fr)
Other versions
WO2008148492A1 (en
Inventor
Peter Berndt
Bernd Bohrmann
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of WO2008148492A1 publication Critical patent/WO2008148492A1/en
Publication of WO2008148492A8 publication Critical patent/WO2008148492A8/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a method for assessing Alzheimer's disease in vitro comprising measuring in a sample (e.g. body fluid) the level of one or more proteins of the group consisting of Neurofilament triplet M protein and Alpha-internexin, or a variant thereof, wherein an altered level of said one or more proteins, or a variant thereof, is indicative that said individual suffers from Alzheimer's Disease. Furthermore, the present invention relates to a method for monitoring the progression of the Alzheimer's disease in vitro comprising measuring in a sample (e.g. body fluid) the level of one or more proteins of the group consisting of Neurofilament triplet M protein and Alpha- internexin, or a variant thereof, wherein an altered level of said one or more proteins, or a variant thereof, compared with an earlier measurement of the level of said one or more proteins, or a variant thereof, is indicative for the progression of Alzheimer's disease.
PCT/EP2008/004237 2007-06-04 2008-05-28 Neurofilamental proteins as biomarker for alzheimer's disease WO2008148492A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07109520 2007-06-04
EP07109520.2 2007-06-04

Publications (2)

Publication Number Publication Date
WO2008148492A1 WO2008148492A1 (en) 2008-12-11
WO2008148492A8 true WO2008148492A8 (en) 2009-11-05

Family

ID=39719261

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/004237 WO2008148492A1 (en) 2007-06-04 2008-05-28 Neurofilamental proteins as biomarker for alzheimer's disease

Country Status (1)

Country Link
WO (1) WO2008148492A1 (en)

Also Published As

Publication number Publication date
WO2008148492A1 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
WO2006113245A3 (en) Methods for measuring glycan levels of proteins
WO2008089994A8 (en) Use of igfbp-7 in the assessment of heart failure
KR100711046B1 (en) Use of nicotinamide n-methyltransferase as a marker for colorectal cancer
HK1115636A1 (en) Use of cyfra 21-1 as a marker for colorectal cancer cyfra 21-1
ATE554389T1 (en) APEX AS A MARKER FOR LUNG CANCER
WO2007062090A8 (en) Methods and compositions related to b cell assays
WO2007114986A3 (en) Cooperative probes and methods of using them
WO2007136980A3 (en) Diagnostic test media and methods for the manufacture thereof
WO2008021515A3 (en) Methods of determining levels of free amino acids and dipeptides and diagnosing alzheimer's diseases
DK2021794T3 (en) Use of protein S100A 12 as a marker for colorectal cancer
BRPI0812875B8 (en) "IN VITRO METHOD TO IDENTIFY WHETHER OR NOT AN INDIVIDUAL IS AT RISK FOR DEVELOPING SEVERE SEPSIS, AND, TEST KIT
EP1930445A4 (en) Kit and method for detection of urothelial cancer
WO2010061283A3 (en) Biomarkers for diagnosing and detecting the progression of neurodegenerative disorders, in particular of amyotrophic lateral sclerosis
WO2007117330A3 (en) Latent protein c assays and their uses for diagnosis and/or prognosis in systemic inflammatory response syndromes
WO2006092729A3 (en) Novel biomarkers for diagnosis and/or prognosis or prognosis of neoplasias in animals
WO2006113289A3 (en) Saposin d and fam3c are biomarkers for alzheimer's disease
HK1136873A1 (en) Use of nnmt as a marker for lung cancer
AU2010202926B2 (en) Markers and methods relating to the assessment of Alzheimer's disease
WO2008117027A3 (en) Altered mitochondrial activity in diseases resulting from oxidative stress
DE602006015702D1 (en) DISTINCTION BETWEEN BACTERIAL MENINGITIS AND VIRAL MENINGITIS
WO2014117680A3 (en) Use of trpc6 mrna levels in peripheral blood cells for early detection/diagnosis of senile dementia
WO2010000467A8 (en) Asc as a marker for lung cancer
WO2007140971A3 (en) Cell adhesion proteins as biomarker for alzheimer's disease
FR2930036B1 (en) METHOD FOR DIAGNOSING PULMONARY ARTERIAL HYPERTENSION
WO2005040806A3 (en) Use of protein asc as a marker for breast cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08758821

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08758821

Country of ref document: EP

Kind code of ref document: A1